Ferroptosis Involvement in Glioblastoma Treatment.
Andrei Otto MitreAlexandru Ioan FlorianAndrei BuruianaArmand BoerIoana MoldovanOlga SoritauStefan Ioan FlorianSergiu SusmanPublished in: Medicina (Kaunas, Lithuania) (2022)
Glioblastoma multiforme (GBM) is one of the deadliest brain tumors. Current standard therapy includes tumor resection surgery followed by radiotherapy and chemotherapy. Due to the tumors invasive nature, recurrences are almost a certainty, giving the patients after diagnosis only a 12-15 months average survival time. Therefore, there is a dire need of finding new therapies that could potentially improve patient outcomes. Ferroptosis is a newly described form of cell death with several implications in cancer, among which GBM. Agents that target different molecules involved in ferroptosis and that stimulate this process have been described as potentially adjuvant anti-cancer treatment options. In GBM, ferroptosis stimulation inhibits tumor growth, improves patient survival, and increases the efficacy of radiation and chemotherapy. This review provides an overview of the current knowledge regarding ferroptosis modulation in GBM.
Keyphrases
- cell death
- locally advanced
- cell cycle arrest
- end stage renal disease
- early stage
- minimally invasive
- newly diagnosed
- chronic kidney disease
- ejection fraction
- healthcare
- radiation induced
- radiation therapy
- prognostic factors
- papillary thyroid
- case report
- squamous cell carcinoma
- coronary artery bypass
- rectal cancer
- peritoneal dialysis
- patient reported outcomes
- percutaneous coronary intervention
- acute coronary syndrome
- patient reported
- coronary artery disease
- young adults
- childhood cancer